Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Suzanne Hayman, MD, Morie Gertz, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Susan Geyer, PhD, Shaji Kumar, MD, Steven Zeldenrust, MD, Stephen Russell, MD, PhD, John Lust, MD, PhD, Robert Kyle, MD, Philip Greipp, MD, Thomas Witzig, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3568.

https://doi.org/10.1182/blood.V108.11.3568.3568

Published: 2006

Journal Articles

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Martha Lacy, MD, Morie Gertz, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Susan Geyer, PhD, Steven Zeldenrust, MD, Shaji Kumar, MD, Philip Greipp, MD, Rafael Fonseca, MD, John Lust, MD, Stephen Russell, MD, PhD, Robert Kyle, MD, Thomas Witzig, MD, Leif Bergsagel, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 798.

https://doi.org/10.1182/blood.V108.11.798.798

Published: 2006

Journal Articles

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

George Weiner, MD, Gregory Wiseman, MD, Thomas Witzig, MD, Brian Link, MD, James Wooldridge, MD, James Ponto, MD, Malik Juweid, MD

Blood (2005) 106 (11): 2823.

https://doi.org/10.1182/blood.V106.11.2823.2823

Published: 2005

Journal Articles

A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

Andres Forero-Torres, MD, Jatin Shah, MD, Stephen Besh, MD, Susan Knox, MD, Ivana Micallef, MD, George Wiseman, M.D, Thomas Witzig, MD, Albert Lobuglio, MD, Sui Shen, PhD, Michael Goris, MD, Jeanne Connor, Ruby Meredith, MD, PhD

Blood (2005) 106 (11): 4798.

https://doi.org/10.1182/blood.V106.11.4798.4798

Published: 2005

Journal Articles

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Cristina Joao, MD, Luis F. Porrata, MD, Thomas Witzig, MD, Paul Kurtin, Ivana Micallef, MD, Svetomir N. Markovic, MD, PhD, Charles Erlichman, MD, Anne Novak, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 1495.

https://doi.org/10.1182/blood.V106.11.1495.1495

Published: 2005

Journal Articles

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Irene M. Ghobrial, MD, Mona Melhem, MD, Ujjal Singha, PhD, Diane George, Michael Timm, MD, Lanie Francis, MD, Yazan Alsayed, MD, Alissa Huston, MD, G. David Roodman, MD, PhD, Philip Greipp, MD, Morie Gertz, MD, Thomas Witzig, MD

Blood (2005) 106 (11): 993.

https://doi.org/10.1182/blood.V106.11.993.993

Published: 2005

NARROW

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only